Rigel Pharma Cash Flow - Quarterly (NASDAQ:RIGL)

Add to My Stocks
$3.32 $0.27 (7.52%) RIGL stock closing price Sep 20, 2018 (Closing)

The financial analysis of RIGL requires an investor to check the cash flows for Rigel Pharma. This report provides details about cash inflows and outflows due to the company's business and investment activities, and summarize cash outflows for a given quarter. For Rigel Pharma profits one has to check the income statement and for Rigel Pharma debt one has to check the balance sheet. This statement can tell if a company is running out of money while still being profitable and is useful in Rigel Pharma stock analysis. Rigel Pharma had a negative net income cash flow of $-49.94M till this quarter of 2018 Q2. This report is very useful in measuring the short term viability of a company. Rigel Pharma has a positive cash and cash equivalents change of $26.79M.

View and download details of Rigel Pharma cash flows for latest & last 40 quarters
show more
Quarterly
Annual
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q1
Net Income Cash Flow
-49.94M-24.38M-77.99M-52.12M-34.46M-15.31M-69.21M-53.62M-30.99M-17.46M
Depreciation Depletion Amortization Cash-Flow-0.04M-0.02M----1.05M---
Net Increase (Decrease) in Assets Liabilities-3.05M-0.52M-5.43M-8.56M-7.72M-6.25M-15.79M-16.08M-13.89M-6.71M
Cash From (used in) Discontinued Operations----------
Other Adjustments Net2.65M1.54M5.75M2.69M1.81M-8.06M5.48M3.45M1.43M
Net Cash from (used by) Operating Activities
-50.39M-23.39M-77.55M-57.84M-40.23M-20.76M-75.88M-63.42M-40.85M-22.42M
Increase (Decrease) in Prop Plant And Equipment-0.88M-0.19M-----0.71M-0.79M-0.54M-0.32M
Acquisition Disposition of Subsidiaires----------
Increase (Decrease) in Investments7.9M23.41M-20.04M15.14M7.52M-0.84M25.59M23.56M12.92M-6.44M
Other Cash Inflow (Outflow) from Investment Activities----------
Net Cash from (used by) Investment Activities
7.02M23.21M-19.47M15.76M8.2M-0.15M24.88M22.77M12.37M-6.77M
Issuance (Purchase) of Equity Shares70.16M2.01M117.68M50.32M46.98M43.42M25.18M23.14M9.96M-
Issuance (Repayment) of Debt Securities----------
Increase (Decrease) in Bank & Other Borrowings----------
Payment of Dividends & Other Cash Distributions----------
Other Cash from (used by) Financing Activities----------
Net Cash from (used by) Financing Activities
70.16M2.01M117.68M50.32M46.98M43.42M25.18M23.14M9.96M-
Effect of Exchange Rate Changes on Cash----------
Net Change in Cash & Cash Equivalents
26.79M1.83M20.65M8.24M14.95M22.51M-25.82M-17.5M-18.51M-29.18M
Cash & Equivalents at Beginning of Year38.29M17.63M43.45M15.2M20.85M33.48M18.63M8.87M14.71M46M
Cash & Equivalents at Year End65.08M40.12M38.29M25.87M32.59M40.14M17.63M25.95M24.94M14.26M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

While Rigel Pharma stock price history provides the price history of a stock, Rigel Pharma stock comparison chart shows the same in comparison to peers, and cash flow statements provide cash position of the company. Common terms used in the statement of cash flows are:

  • Net Change in Cash and Cash Equivalents: A positive net change in cash and cash equivalents shows that Rigel Pharma is able to meet its expenditure and grow cash at hand which demonstrates the financial strength of the company's balance sheet. Also see - Rigel Pharma stock price movement.
  • Rigel Pharma decreased its cash from operating activities to $-50.39M till 2018 Q2. Operating activities include production of goods or creating a product or providing a service, and collecting payment for the same from customers. The cash generated from these activities is refered to as cash flow from operating activities.
  • Cash Flow from investment activities: Rigel Pharma generated $7.02M cash due to investment activities. It includes the use of cash outside of normal day to day activities like buying fixed assets, plant and machinery etc.
  • Cash Flow from financing activities: The cash inflow/outflow from financing activities was $70.16M for Rigel Pharma. The money accounted for under this head comes from external sources which includes lenders, investors and shareholders. Positive cash flow is generated when the company gets cash because of issuance of stocks or bonds. Similarly negative cash flow is generated when shares are repurchased, dividend payments are made, and loans or interest on loans are paid back.

Key Financial Ratios For Rigel Pharma Cash Flow

Quarterly Cash Flow Statements For Rigel Pharmaceuticals, Inc. Peers

CASI Pharma cash flow, Collegium Pharma cash flow, Cynapsus Therapeutics cash flow, Johnson & Johnson cash flow